SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:e4297468-cc47-46e4-aebe-78d0333a98ac"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:e4297468-cc47-46e4-aebe-78d0333a98ac" > Apalutamide in Pati...

  • Chi, Kim N.Vancouver Prostate Centre (författare)

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer : Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

  • Artikel/kapitelEngelska2021

Förlag, utgivningsår, omfång ...

  • 2021
  • 10 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:e4297468-cc47-46e4-aebe-78d0333a98ac
  • https://lup.lub.lu.se/record/e4297468-cc47-46e4-aebe-78d0333a98acURI
  • https://doi.org/10.1200/JCO.20.03488DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • PURPOSE: The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving ongoing androgen deprivation therapy (ADT). Herein, we report final efficacy and safety results after unblinding and placebo-to-apalutamide crossover. METHODS: Patients with mCSPC (N = 1,052) were randomly assigned 1:1 to receive apalutamide (240 mg QD) or placebo plus ADT. After unblinding in January 2019, placebo-treated patients were allowed to receive apalutamide. Efficacy end points were updated using the Kaplan-Meier method and Cox proportional-hazards model without formal statistical retesting and adjustment for multiplicity. Change from baseline in Functional Assessment of Cancer Therapy-Prostate total score was assessed. RESULTS: With a median follow-up of 44.0 months, 405 OS events had occurred and 208 placebo-treated patients (39.5%) had crossed over to apalutamide. The median treatment duration was 39.3 (apalutamide), 20.2 (placebo), and 15.4 months (crossover). Compared with placebo, apalutamide plus ADT significantly reduced the risk of death by 35% (median OS not reached v 52.2 months; hazard ratio, 0.65; 95% CI, 0.53 to 0.79; P < .0001) and by 48% after adjustment for crossover (hazard ratio, 0.52; 95% CI, 0.42 to 0.64; P < .0001). Apalutamide plus ADT delayed second progression-free survival and castration resistance (P < .0001 for both). Health-related quality of life, per total Functional Assessment of Cancer Therapy-Prostate, in both groups was maintained through the study. Safety was consistent with previous reports. CONCLUSION: The final analysis of TITAN confirmed that, despite crossover, apalutamide plus ADT improved OS, delayed castration resistance, maintained health-related quality of life, and had a consistent safety profile in a broad population of patients with mCSPC.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Chowdhury, SimonGuy's and St Thomas' NHS Foundation Trust (författare)
  • Bjartell, AndersLund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Urological cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)kir-abj (författare)
  • Chung, Byung HaSeverance Hospital (författare)
  • Pereira de Santana Gomes, Andrea J.Liga Norte Riograndense Contra o Câncer (författare)
  • Given, RobertEastern Virginia Medical School (författare)
  • Juárez, AlvaroHospital Universitario de Jerez de la Frontera (författare)
  • Merseburger, Axel S.University Medical Center Schleswig-Holstein (författare)
  • Özgüroğlu, MustafaIstanbul University (författare)
  • Uemura, HirotsuguKindai University Hospital (författare)
  • Ye, DingweiFudan University Shanghai Cancer Center (FUSCC) (författare)
  • Brookman-May, SabineJanssen Research & Development, Belgium,Ludwig-Maximilian University of Munich (författare)
  • Mundle, Suneel D.Janssen Research & Development, Belgium (författare)
  • McCarthy, Sharon A.Janssen Research & Development, Belgium (författare)
  • Larsen, Julie S.Janssen Research & Development, Belgium (författare)
  • Sun, WeiliJanssen Research & Development, Belgium (författare)
  • Bevans, Katherine B.Janssen Research & Development, Belgium (författare)
  • Zhang, KeJanssen Research & Development, Belgium (författare)
  • Bandyopadhyay, NibeditaJanssen Research & Development, Belgium (författare)
  • Agarwal, NeerajHuntsman Cancer Institute (författare)
  • Vancouver Prostate CentreGuy's and St Thomas' NHS Foundation Trust (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of clinical oncology : official journal of the American Society of Clinical Oncology39:20, s. 2294-23030732-183X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy